[go: up one dir, main page]

SV1999000049A - Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv - Google Patents

Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv

Info

Publication number
SV1999000049A
SV1999000049A SV1999000049A SV1999000049A SV1999000049A SV 1999000049 A SV1999000049 A SV 1999000049A SV 1999000049 A SV1999000049 A SV 1999000049A SV 1999000049 A SV1999000049 A SV 1999000049A SV 1999000049 A SV1999000049 A SV 1999000049A
Authority
SV
El Salvador
Prior art keywords
substituted
diethydropyrimidines
new
heterociclicamente
ref
Prior art date
Application number
SV1999000049A
Other languages
English (en)
Inventor
Siegfried Goldmann
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SV1999000049A publication Critical patent/SV1999000049A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVAS DIHIDROPIRIMIDINAS 2 HETEROCICLICAMENTE SUSTITUIDAS, A MEDICAMENTOS QUE CONTIENEN ESTAS DIHIDROPIRIMIDINAS 2 HETEROCICLICAMENTE SUSTITUIDAS, ASI COMO A UN PROCEDIMIENTO PARA LA PREPARACION DE MEDICAMENTOS. AL INVENCION SE REFIERE ADEMAS AL USO DE DIHIDROPIRIMIDINAS 2 HETEROCICLICAMENTE SUSTITUIDAS PARA LA PREPARACION DE UN MEDICAMENTO, EN ESPECIAL PARA EL TRATAMIENTO DE ENFERMEDADES VIRICAS AGUDAS O CRONICAS, ESPECIALMENTE PARA LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE INFECCIONES AGUDAS O CRONICAS POR HEPATITIS B.
SV1999000049A 1998-04-18 1999-04-16 Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv SV1999000049A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19817262A DE19817262A1 (de) 1998-04-18 1998-04-18 Neue 2-heterocyclisch substituierte Dihydropyrimidine

Publications (1)

Publication Number Publication Date
SV1999000049A true SV1999000049A (es) 2000-07-04

Family

ID=7864971

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1999000049A SV1999000049A (es) 1998-04-18 1999-04-16 Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv

Country Status (15)

Country Link
US (1) US6503913B1 (es)
EP (1) EP1073653B1 (es)
JP (1) JP2002512244A (es)
KR (1) KR20010042787A (es)
CN (1) CN1134434C (es)
AR (1) AR015765A1 (es)
AU (1) AU3420599A (es)
CA (1) CA2328876A1 (es)
DE (2) DE19817262A1 (es)
ES (1) ES2181413T3 (es)
GT (1) GT199900055A (es)
ID (1) ID26308A (es)
PE (1) PE20000428A1 (es)
SV (1) SV1999000049A (es)
WO (1) WO1999054329A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4289100A (en) * 1999-03-25 2000-10-16 Bayer Aktiengesellschaft Dihydropyrimidines and their use in the treatment of hepatitis
AU5568400A (en) 1999-06-23 2001-01-09 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
WO2001045712A1 (de) * 1999-12-22 2001-06-28 Bayer Aktiengesellschaft Arzneimittelkombinationen gegen virale erkrankungen
DE10012549A1 (de) * 2000-03-15 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012824A1 (de) * 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013125A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
JP2009530401A (ja) * 2006-03-24 2009-08-27 ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ フェノールヒドラゾンマクロファージ転移阻害因子阻害剤
CN101104617B (zh) 2006-07-10 2010-06-23 北京摩力克科技有限公司 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN101104604B (zh) 2006-07-10 2011-03-02 北京摩力克科技有限公司 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
CN100453542C (zh) * 2007-04-30 2009-01-21 广东东阳光药业有限公司 2-杂环取代的二氢嘧啶消旋化合物的拆分方法
CN101328170B (zh) * 2007-06-18 2011-09-14 张中能 一种氟苯基-取代噻唑二氢嘧啶
CN101328168B (zh) * 2007-06-18 2011-09-07 张中能 一种乙氧碳酰基-取代噻唑二氢嘧啶
AU2008265397C1 (en) 2007-06-18 2013-08-29 Sunshine Lake Pharma Co., Ltd. Bromo-phenyl substituted thiazolyl dihydropyrimidines
WO2010069147A1 (zh) * 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用
AR089671A1 (es) * 2012-01-06 2014-09-10 Janssen R & D Ireland 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CA3132120C (en) 2012-02-08 2023-10-24 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
KR20140143160A (ko) * 2012-03-31 2014-12-15 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 및 예방을 위한 신규한 4-메틸-다이하이드로피리미딘
PL2888241T3 (pl) 2012-08-24 2017-12-29 Sunshine Lake Pharma Co., Ltd. 2,4,5,6-Podstawione pochodne 3,6-dihydropirymidyny jako inhibitory polimerazy wirusa zapalenia wątroby typu B (HBV) do leczenia np. przewlekłego zapalenia wątroby
CN103664925B (zh) * 2012-09-07 2018-01-23 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
BR112015004113A2 (pt) 2012-09-10 2017-07-04 Hoffmann La Roche 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
MX2016006564A (es) 2013-11-19 2017-09-12 Sunshine Lake Pharma Co Ltd Compuestos dihidropirimidina y su aplicacion en productos farmaceuticos.
KR102284938B1 (ko) * 2013-11-27 2021-08-02 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법
MX2016012573A (es) 2014-03-28 2018-02-19 Sunshine Lake Pharma Co Ltd Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
TW201629054A (zh) 2015-02-07 2016-08-16 廣東東陽光藥業有限公司 二氫嘧啶衍生物的複合物及其在藥物中的應用
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10179131B2 (en) * 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
AU2016326704B2 (en) 2015-09-23 2021-01-28 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses
US10253030B2 (en) 2015-11-04 2019-04-09 Qilu Pharmaceutical Co., Ltd. Crystal form, preparation method and intermediate of dihydropyrido ring compound
WO2017136403A1 (en) 2016-02-02 2017-08-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
SG11201807543YA (en) 2016-03-07 2018-09-27 Enanta Pharm Inc Hepatitis b antiviral agents
CA3028228A1 (en) * 2016-06-10 2017-12-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
JP2019523279A (ja) 2016-07-29 2019-08-22 サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. 化合物および組成物ならびにそれらの使用
SG11201900689RA (en) 2016-07-29 2019-02-27 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
AU2018312559B2 (en) 2017-08-02 2022-06-02 Pgi Drug Discovery Llc Isochroman compounds and uses thereof
CN107501257B (zh) * 2017-08-17 2020-05-29 山东大学 二氢嘧啶-三氮唑类衍生物及其制备方法与应用
CA3073986A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
EP3697792A4 (en) * 2017-10-18 2021-10-13 Sunshine Lake Pharma Co., Ltd. DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN MEDICINE
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019113173A1 (en) 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2019143902A2 (en) 2018-01-22 2019-07-25 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
KR20210065965A (ko) 2018-09-21 2021-06-04 이난타 파마슈티칼스, 인코포레이티드 항바이러스제로서 작용화된 헤테로사이클
SG11202105007TA (en) 2018-11-21 2021-06-29 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
AU2020316351A1 (en) 2019-07-19 2022-02-17 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN112707910A (zh) * 2019-10-24 2021-04-27 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN113512035B (zh) * 2021-04-26 2023-11-24 山东大学 二氢嘧啶-泊马度胺缀合物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH550189A (de) 1971-01-08 1974-06-14 Ciba Geigy Ag Verfahren zur herstellung von neuen dibenzo (b,f) thiepincarbonsaeuren.
CH569043A5 (es) 1973-01-23 1975-11-14 Ciba Geigy Ag
DE3234684A1 (de) * 1982-09-18 1984-03-22 Bayer Ag, 5090 Leverkusen Neue dihydropyrimidine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln

Also Published As

Publication number Publication date
EP1073653B1 (de) 2002-08-28
CA2328876A1 (en) 1999-10-28
HK1037188A1 (en) 2002-02-01
JP2002512244A (ja) 2002-04-23
AR015765A1 (es) 2001-05-16
GT199900055A (es) 2000-10-07
KR20010042787A (ko) 2001-05-25
WO1999054329A1 (de) 1999-10-28
US6503913B1 (en) 2003-01-07
CN1297449A (zh) 2001-05-30
DE59902470D1 (de) 2002-10-02
AU3420599A (en) 1999-11-08
ID26308A (id) 2000-12-14
CN1134434C (zh) 2004-01-14
PE20000428A1 (es) 2000-06-25
EP1073653A1 (de) 2001-02-07
ES2181413T3 (es) 2003-02-16
DE19817262A1 (de) 1999-10-21

Similar Documents

Publication Publication Date Title
SV1999000049A (es) Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv
SV1999000048A (es) Uso de dihidropiriminas como medicamento y nuevas sustancias ref. lea 32 791-sv
UY26320A1 (es) Sales farmaceuticas de la sustancia activa tramadol y al menos un edulcorante, medicamentos que contienen estas sales, el uso de estas sales para la preparacion de medicamentos y formas de administracion que contienen esas sales. ley 17164
BR0207726A (pt) Sais farmacêuticos
BR0017030B8 (pt) derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos
CY1112361T1 (el) Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743
BR9907647A (pt) Composições contendo composto orgânicos
SV2003001107A (es) Imidazotriazinas ref.lea 35368
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
ES2062392T3 (es) Medicamentos que comprenden salmeterol y fluticasona.
BR0102040A (pt) Uso de paclitaxel estabilizado com albumina para preparação de uma droga para o tratamento de tumores sólidos e a droga desse modo obtida
BR0214469A (pt) 17alfa-alquil-17beta-óxi-estratrienos e produtos intermediários para sua preparação, aplicação dos 17alfa-alquil-17beta-óxi-estratrienos para a preparação de medicamentos bem como preparações farmacêuticas
BRPI0411484A (pt) composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
DK1162982T3 (da) Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning
AR036813A1 (es) Composiciones farmaceuticas
BR0211198A (pt) Composições farmacêuticas e seu uso
SE9702401D0 (sv) Pharmaceutical use
BR0107493A (pt) Substâncias para uso no tratamento de psorìase
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
CL2004001068A1 (es) Compuestos derivados de 2,3,4,5-tetrahidrobenzo[f][1,4]oxazepina; procedimientos de preparacion; composicion farmaceutica que los contiene y su uso en la elaboracion de un medicamento util para el tratamiento de la enfermedad de alzheimer.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
IT1241079B (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
BRPI0607614A2 (pt) sal de besilato da 7-(2-(4-3-trifluorometil-fenil)-1,2,3,6-tetrahidropirid- 1-il)etil) isoquinoleìna, o respectivo medicamento, composição farmacêutica e uso